Sidney Kimmel Cancer Center makes personnel changes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

SIDNEY KIMMEL CANCER CENTER at Johns Hopkins University made several personnel changes.

Kenneth Cohen was named associate director of integration and strategic relationships for the Department of Oncology. In this role, Cohen will work with faculty members and administration to represent the interests of the department and the Cancer Center in discussions and negotiations with outside entities.

Charles Drake was appointed co-director of the Kimmel Cancer Center’s Immunology Program. He joins Drew Pardoll in leading the program. In addition to his research responsibilities, Drake is a clinical oncologist specializing in prostate, kidney, bladder and testicular cancers.

Khinh Ranh Voong has been appointed instructor in the Department of Radiation Oncology and Molecular Radiation Sciences, where she will be a part of the thoracic oncology team based at Johns Hopkins Bayview Medical Center.

Syed Ali was appointed as an instructor in oncology for the Division of Hematologic Malignancies. Ali will focus on novel and immune-based approaches for the treatment of multiple myeloma. He will serve as an attending on the inpatient hematologic malignancy service, supervise fellows’ clinic, participate in bone marrow reading and see patients in clinic.

Nilanjan Chatterjee has joined the faculty as a Bloomberg Distinguished Professor with a dual appointment in the Department of Oncology’s Division of Biostatistics and Bioinformatics and in the Department of Biostatistics at the Bloomberg School of Public Health.

Doug Smith, of the Department of Oncology’s Division of Hematologic Malignancies, was promoted to professor of oncology.

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login